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Abstract Ultraviolet B (UVB) irradiation, the major damaging
component of sunlight, has earlier been reported to enhance
cutaneous angiogenesis in chronically sun-exposed skin. We
herein provide first evidence for a biphasic induction of the
vascular endothelial growth factor (VEGF) following UVB
irradiation of the human epidermal cell line HaCaT. The first
VEGF peak occurred on mRNA level at 1 h and on protein level
at 4 h postirradiation and is fully mediated by the UVB-
dependent phosphorylation of the epidermal growth factor
receptor, which subsequent to its phosphorylation also initiates
at least in part the synthesis of transforming growth factor K that
confers as shown previously the second late VEGF peak at 8 h on
mRNA and at 24 h on protein level.
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1. Introduction
Chronically sun-exposed skin is characterized by wide-
spread teleangiectasia, an increase in small blood vessels,
and vascularized malignant tumors [1]. There is increasing
evidence that the induction of angiogenesis precedes the for-
mation of malignant tumors [2^6], suggesting that angiogen-
esis is not only crucial for tumor expansion, but also for the
onset of malignancy. Among a variety of angiogenic growth
factors, vascular endothelial growth factor (VEGF), also
known as vascular permeability factor, is a dimeric glycopro-
tein with a molecular weight of 34^45 kDa [7^11] that due to
alternative splicing comprises di¡erent molecular isoforms
[12,13]. VEGF induces microvascular hyperpermeability and
represents a selective mitogen for endothelial cells [9,14].
VEGF exerts its biological e¡ects by binding to its receptors
VEGF-R1 (£t-1) and VEGF-R2 (£k/KDR) which are mainly
expressed in endothelial cells [15^18]. Blocking of the VEGF
function inhibits angiogenesis in the mouse cornea [19] and
suppresses tumor growth and invasion [6,17,20^22]. Previous
¢ndings with ultraviolet B (UVB) induced up-regulation of
VEGF in normal murine and human skin [23^25], in squa-
mous cell carcinomas of sun-exposed anatomical sites
[24,26,27] and suppression of UVB-induced angiogenesis in
hairless mice upon intraperitoneal administration of neutral-
izing antibodies against VEGF supports the causal role of
VEGF in angiogenesis after UVB irradiation in vivo. In fur-
ther attempts to clarify the mechanistic base for the UVB
induction of VEGF in more detail, most laboratories includ-
ing ours [23,24,28,29] have found a late induction of VEGF
protein synthesis and release occurring between 12 and 24 h
postirradiation in a variety of epidermal cell lines and primary
keratinocytes. In this study, we provide ¢rst evidence for a
biphasic induction of VEGF on mRNA and protein level
upon UVB irradiation of the human epidermal cell line Ha-
CaT at a physiological dose of 10 mJ/cm2. The ¢rst peak of
VEGF165 expression is due to the UVB-induced phosphory-
lation and activation of the epidermal growth factor receptor
(EGF-R) and most likely initiates the earlier published release
of transforming growth factor K (TGFK) starting at 6 h,
which via autocrine binding and activation of the EGF-R is
responsible for the second peak of VEGF release [28]. The
identi¢cation of UVB-induced activation of the EGF-R
underlying the ¢rst peak of VEGF release and its causal in-
terrelation to the second VEGF peak in the biphasic UVB
response may promote the development of selective, non-toxic
inhibitors of the enhanced EGF-R function.
2. Materials and methods
2.1. Reagents
Cell culture medium Dulbecco’s modi¢ed Eagle’s medium (DMEM)
and Trizol0 reagent were from Life Technologies (Eggenstein, Ger-
many) and fetal calf serum (FCS) from Biochrom (Berlin, Germany).
All chemicals and biochemicals were obtained from Sigma (Deisenho-
fen, Germany) unless otherwise indicated. A mouse anti-human
TGFK neutralizing antibody was purchased from Calbiochem (Bad
Soden, Germany). Mouse anti-human EGF-R, mouse anti-phospho-
tyrosine and rabbit anti-mouse horseradish peroxidase (HRP) were
from Santa Cruz Biotechnology (Heidelberg, Germany). The EGR-
R-speci¢c tyrosine kinase inhibitor PD 153035 was from Calbiochem
(Bad Soden, Germany). VEGF165 enzyme-linked immunosorbent as-
say (ELISA) kits were obtained by RpD Systems (Wiesbaden-Nor-
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denstadt, Germany). Protein A agarose was from Santa Cruz Biotech-
nology (Heidelberg, Germany).
2.2. Cell culture
The human epidermal cell line HaCaT was cultured in DMEM
supplemented with glutamine (2 mM), penicillin (400 U/ml), strepto-
mycin (50 Wg/ml), 10% FCS and grown on plastic tissue culture dishes
in a humidi¢ed atmosphere of 5% CO2 and 95% air at 37‡C [30].
2.3. Light source and UVB irradiation
A 1000 W xenon high-pressure UV source was used in conjunction
with a monochromator with holographic grating (Dermolum UMW,
Fa. Mu«ller, Moosinning, Germany). For the experiments, the total
UVB spectrum (280^320 nm) was used. Fluences were determined
by an integrated thermophile. The dose rates on the cell surface
were 0.4 mW/cm2 for the total UVB spectrum. To guarantee a con-
stant intensity and spectral distribution, dosimetry and spectroradio-
metric analysis were performed prior to experiments with an OL-754
UV/visible light spectroradiometer (Optronic, Orlando, FL, USA).
Subcon£uent monolayer cultures of HaCaT cells were rinsed twice
with phosphate-bu¡ered saline (PBS) and thereafter irradiated under
a thin layer of PBS at a dose of 10 or 50 mJ/cm2 of the complete UVB
spectrum [31]. There was negligible loss in viability of cell populations
compared to cells held under similar conditions without irradiation.
Following UVB irradiation, cells were replenished with their own
medium or cultivated in DMEM without FCS for various periods
of time. UVB doses applied in this study are relevant and easily reach
basal keratinocytes in vivo [32].
2.4. ELISA
The cytokine ELISA assay was performed according to the manu-
facturer’s protocol. Concentrations of the VEGF165 protein were
measured in cell culture supernatants using a quantitative sandwich
ELISA (RpD Systems, Wiesbaden-Nordenstadt, Germany). Four
hours before collecting the supernatants of the irradiated cells, the
conditioned medium was replaced by serum-free DMEM. The con-
centrations of VEGF165 to be tested in the samples were determined
against standard curves using GraphPad1 software (San Diego, CA,
USA). Means and S.D. were calculated, and the signi¢cance of the
values was tested by the Student’s t test or analysis of variance (AN-
OVA) (InStat software, GraphPad, San Diego, CA, USA).
2.5. Isolation of total RNA and RNase protection assay
Total RNA was extracted from HaCaT cells with Trizol0 according
to the manufacturer’s recommendation (Life Technologies). The
RNase protection assay was performed as published [33]. Densitomet-
ric analysis was performed using Scan Pack II software (Biometra,
Go«ttingen, Germany).
2.6. Neutralization and inhibition studies
Two hours prior and directly after UVB irradiation at a dose of 10
mJ/cm2, subcon£uent HaCaT cells were incubated with neutralizing
mouse anti-human antibodies speci¢c for TGFK at concentrations of
100 and 500 ng/ml. For inhibition of EGF-R-mediated signal trans-
duction, quiescent HaCaT cells were incubated with distinct concen-
trations of an inhibitor of tyrosine kinase phosphorylation highly
speci¢c for the EGF-R, 4-[(bromophenyl)amino]-6,7-dimethoxyquina-
zoline (PD 153035, Calbiochem, Bad Soden, Germany), 2 h prior to
and 4 h after UVB irradiation at a dose of 10 mJ/cm2. Four hours
after UVB irradiation, the supernatants were collected for determina-
tion of VEGF165 protein levels.
2.7. Analysis of EGF-R tyrosine phosphorylation
Subcon£uent HaCaT cell cultures were washed twice with ice-cold
PBS and scraped into 0.5 ml of lysis bu¡er (20 mM imidazole, 100
mM KCl, 1 mM MgCl2, 200 mM EGTA, 0.5% Triton X-100, 150 nM
aprotinin, 2 WM leupeptin, 1.5 WM pepstatin A, 1 mM PMSF, 10 mM
NaF, 200 mM Na2MoO4W2H2O, 1 mM Na3VO4 (pH 10)). After so-
ni¢cation, 800 Wl of cellular lysate (protein concentration of 1.25 Wg/
Wl) was precleared with protein A agarose (Santa Cruz Biotechnology,
Heidelberg, Germany) for 1 h at 4‡C. Immunoprecipitation was per-
formed overnight at 4‡C using a monoclonal antibody speci¢c for
human EGF-R (Santa Cruz Biotechnology, Heidelberg, Germany).
The protein A agarose pellets were washed three times with Tris-
bu¡ered saline (TBS) (4‡C), boiled in 60 Wl of 2Usample bu¡er
(100 mM Tris^HCl (pH 6.8), 4% sodium dodecyl sulfate (SDS),
0.2% bromophenol blue, 20% glycerol, 5% 2-mercaptoethanol) for
5 min and the proteins were resolved by SDS^PAGE. Proteins were
transferred to Protran nitrocellulose membrane (Schleicher and
Schu«ll, Dassel, Germany), and the membrane was blocked in 1%
blocking bu¡er (1% casein, 1% polyvinylpyrrolidone in TBS (pH
7.2)) for 1 h. For immunodetection of phosphorylated EGF-R, an
anti-phosphotyrosine antibody (PY99, Santa Cruz Biotechnology,
Heidelberg, Germany) was added to 0.5% blocking bu¡er plus 0.1%
PEG-6000 at a concentration of 0.1 Wg/ml. Staining was performed
with a HRP-linked antibody (Santa Cruz Biotechnology, Heidelberg,
Germany) which was visualized using Luminol ECL detection reagent
(Santa Cruz Biotechnology, Heidelberg, Germany). Densitometric
analysis was performed using Scan Pack II software (Biometra, Go«t-
tingen, Germany).
2.8. Cytotoxicity assay
The viability of HaCaT cells was measured 24 h after UVB irradi-
ation at di¡erent doses. 3-(4,5-Dimethylthiazole-2-yl)-2,5-diphenyl-tet-
razolium bromide (MTT) (Sigma, Deisenhofen, Germany) was used
for the quanti¢cation of living metabolically active cells. Mitochon-
drial dehydrogenases metabolize MTT to purple formazan dye [34].
Cytotoxicity was calculated as percent of formazan formation in cells
which have been irradiated compared to mock-treated cells.
3. Results and discussion
3.1. Biphasic induction of the VEGF upon UVB irradiation of
HaCaT cells
Recently, several laboratories reported on the induction of
VEGF in human epidermal cell lines (A431, HaCaT) and
human primary keratinocytes in vitro and in vivo following
UVB irradiation [23,24,28,29]. These studies including our
own [28] reported on the monophasic induction of VEGF
mRNA and protein levels occurring between 4 and 24 h post-
irradiation. An exact time-dependent response curve has,
however, not yet been established. Using a highly speci¢c
sandwich ELISA, we have monitored the protein level of
the VEGF165 isoform at di¡erent time points postirradiation.
Exposure of HaCaT cells to a low UVB dose of 10 mJ/cm2
resulted in a ¢rst peak with a 2.3-fold increase in the speci¢c
VEGF165 protein concentration at 4 h postirradiation, while a
second 4-fold increase was observed at 24 h postirradiation
(Fig. 1a). At the used UVB dose of 10 mJ/cm2, s 80% of the
HaCaT cells were viable 24 h postirradiation (Fig. 1a, inset).
Interestingly, this biphasic response VEGF165 protein concen-
tration was also re£ected on mRNA level as determined by a
previously established RNase protection assay [23] with sub-
sequent densitometric analysis. Exposure of HaCaT cells to a
UVB dose of 10 mJ/cm2 resulted in a ¢rst peak of speci¢c
VEGF165 mRNA level with a 1.8-fold induction already 1 h
postirradiation and a second increase in VEGF165 mRNA
level of 2.3-fold was observed at 12 h when compared to
mock-treated control cells. Similar results were obtained for
speci¢c mRNA levels of VEGF121 (Fig. 1b). These data in-
dicate a biphasic response of VEGF synthesis on mRNA and
protein level following UVB irradiation. Our data, as based
on the speci¢c ELISA for VEGF165, do not allow to monitor
the contribution of cell surface-associated VEGF isoforms to
the overall VEGF levels upon exposure of HaCaT cells to
UVB irradiation. There is, however, evidence that UVB irra-
diation most likely via the proteolytic direct cleavage of the
cell-associated VEGF189 isoform by the urokinase-type plas-
minogen activator (uPA) and via proteolytic conversion of cell
surface bound plasminogen to plasmin and subsequent cleav-
age of cell surface-associated VEGF189 and VEGF165 [35,36]
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may contribute to the release of the cell surface bound VEGF
isoforms. This interesting question awaits further elucidation
in an independent study.
3.2. UVB irradiation results in a time-dependent increase in
phosphorylation of the EGF-R
UVB irradiation has been reported to be able to phosphor-
ylate and activate the EGF-R in the absence of ligands in the
cervix carcinoma cell line HeLa [37]. This UVB-induced tyro-
sine phosphorylation re£ects EGF-R activation and leads to
the recruitment of adaptor proteins and other postreceptor
events [38]. Also, EGF-R phosphorylation was found in hu-
man keratinocytes after exposure to UVB [39]. In order to
analyze a potential regulatory role of EGF-R phosphory-
lation, which may be responsible for the ¢rst peak of the
UVB-dependent biphasic VEGF induction, we ¢rst estab-
lished a time kinetic of EGF-R phosphorylation upon UVB
irradiation (Fig. 2). Already 5 min postirradiation, a 3.3-fold
with a further time-dependent increase in EGF-R phosphor-
ylation of up to 24-fold at 60 min postirradiation was ob-
served (Fig. 2). All following experiments which aimed at
the inhibition of EGF-R phosphorylation were performed in
the presence of the speci¢c inhibitor PD 153035 [40,41] 2 h
prior to UVB irradiation and during a 4 h postirradiation
period. Similar to our data, a sustained phosphorylated state
Fig. 2. The EGF-R is activated by UVB irradiation. Subcon£uent
quiescent HaCaT cells were irradiated at a dose of 50 mJ/cm2 of
the complete UVB spectrum. Cellular lysates were subjected to
EGF-R phosphorylation analysis at di¡erent time points thereafter.
Densitometric analysis was performed using Scan Pack II software
(Biometra, Go«ttingen, Germany). The blot is representative of two
independently performed experiments.
Fig. 1. VEGF is biphasically up-regulated on protein and mRNA
level after UVB irradiation. (a) Subcon£uent quiescent HaCaT cells
were UVB-irradiated at a dose of 10 mJ/cm2 and the VEGF165 pro-
tein contents of the supernatants were analyzed using a quantitative
sandwich ELISA speci¢c for VEGF165. Conditioned medium from
mock-irradiated cells served as a control. Data are expressed as fold
increase over mock-treated controls which were set one
(mean þ S.D., n = 3). The inset in (a) depicts the UVB dose-depen-
dent decrease in cell viability at 24 h postirradiation as measured by
the MTT cytotoxicity assay further detailed in Section 2. (b) Sub-
con£uent quiescent HaCaT cells were UVB-irradiated at a dose of
10 mJ/cm2 and VEGF mRNA expression for the isoforms VEGF121
(E) and VEGF165 (F) was analyzed by means of RNase protection
assay at the indicated time points. Total RNA from mock-irradiated
cells served as a control. Densitometric analysis was performed us-
ing Scan Pack II software (Biometra, Go«ttingen, Germany).
Fig. 3. The ¢rst UVB-induced peak of VEGF165 protein is due to
EGF-R phosphorylation and independent of TGFK. Incubation of
HaCaT cells 2 h prior to and 4 h after UVB irradiation (10 mJ/
cm2) with neutralizing antibodies speci¢c for hTGFK and subse-
quent analysis of VEGF165 protein in supernatants collected at 4 h
postirradiation did not result in any reduction in VEGF165 protein
concentrations. Incubation of HaCaT cells with distinct concentra-
tions of 4-[(bromophenyl)amino]-6,7-dimethoxyquinazoline (PD
153035), a speci¢c inhibitor of the tyrosine kinase activity of the
EGF-R, 2 h prior to and 4 h after UVB irradiation signi¢cantly re-
duced VEGF165 protein levels (*P6 0.0001 compared to UVB-irra-
diated cells without PD 153035; ANOVA). Data are expressed as
fold increase over mock-treated control which was set one
(mean þ S.D.). Three independent experiments were performed.
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of the EGF-R upon UVB irradiation has earlier been reported
[39,42]. The study by Peus et al. revealed that the phosphor-
ylated state of the EGF-R was still enhanced 2 h postirradia-
tion of human primary keratinocytes at a dose of 40 mJ/cm2.
So far, the underlying molecular mechanisms of the sustained
EGF-R phosphorylation following UVB irradiation are not
entirely clear. There is, however, evidence that UV irradiation
reduces the activity of tyrosyl phosphatases which ultimately
control the phosphorylation state of receptors and proteins
[43,44].
3.3. The ¢rst peak of the biphasic induction of VEGF165 after
UVB irradiation is due to speci¢c phosphorylation and
activation of the EGF-R and, in contrast to the second
VEGF peak, independent of autocrine TGFK
We previously reported that the second late peak of
VEGF165 induction depends at least in part on the UVB-in-
duced phosphorylation of the EGF-R with subsequent release
of TGFK, which, as judged from the complete abrogation of
the second peak by TGFK neutralizing antibodies, is fully
responsible for this second VEGF peak upon UVB irradiation
[28].
In previous experiments (Blaudschun et al., to be published
elsewhere), a time-course analysis demonstrates that at 6 h
postirradiation, but not earlier, a signi¢cant induction of
TGFK occurred after exposure of HaCaT cells at a UVB
dose of 10 mJ/cm2. To further establish whether the UVB-
dependent herein described ¢rst peak of VEGF synthesis, sim-
ilar to the second VEGF peak, is mediated by TGFK, neu-
tralizing antibody experiments were conducted. This was to
exclude the possibility that even minor induction of TGFK at
time points before 6 h postirradiation, which may not be
detected by the TGFK ELISA, contribute to the ¢rst UVB-
induced VEGF peak. By contrast to the complete abrogation
Fig. 4. Molecular mechanisms underlying the biphasic VEGF165 induction after UVB irradiation. UVB irradiation of HaCaT cells leads to a
TGFK-independent phosphorylation and activation of the EGF receptor (a). This activation results in an early peak of VEGF165 on mRNA
and protein level and in addition is responsible for the release of TGFK 6 h postirradiation. Whether the TGFK release is due to TGFK
mRNA synthesis or to preformed TGFK has not been investigated (b). Secreted TGFK subsequently binds to the EGF receptor and leads to a
TGFK-dependent activation of the EGF receptor (c). After this TGFK-dependent EGF-R activation, a second induction in the synthesis of
VEGF165 occurs at 8^24 h after UVB irradiation (d). All time points included in the diagram refer to time point 0 directly after UVB irradia-
tion.
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of the second late peak of VEGF induction with neutralizing
antibodies against TGFK at a concentration of 100 ng/ml [28],
we were unable to reduce the ¢rst VEGF peak following UVB
irradiation with TGFK neutralizing antibodies even at a con-
centration clearly exceeding 100 ng/ml (Fig. 3), indicating that
the ¢rst peak of the biphasic VEGF induction following UVB
irradiation is completely independent of TGFK. As the phos-
phorylation of the EGF-R occurred as early as 5 min post
UVB irradiation, we studied the potential role of this initial
EGF-R phosphorylation in mediating the UVB-dependent
¢rst VEGF peak.
For this purpose, quiescent HaCaT cells were incubated
with an inhibitor of tyrosine kinase phosphorylation highly
speci¢c for the EGF-R, 4-[(bromophenyl)amino]-6,7-di-
methoxyquinazoline (PD 153035) [40,41] 2 h prior to and 4 h
after UVB irradiation. Interestingly, the ¢rst VEGF165 peak
following UVB irradiation could be completely abrogated to
constitutive VEGF165 levels at a non-toxic PD 153035 concen-
tration of 100 nM. The same PD 153035 concentration did
not completely inhibit but reduced the UVB-dependent TGFK
induction to 30% and that of VEGF165 to 35% of the corre-
sponding VEGF induction in UVB-treated cells at 24 h post-
irradiation (Blaudschun et al., submitted). These data suggest
that the initial UVB-dependent EGF-R phosphorylation is
responsible (I) for the ¢rst VEGF peak and (II) is partly
responsible for the TGFK release which, via binding and ac-
tivation of the EGF-R, contributes to the second VEGF peak
(Fig. 4). In fact, binding of TGFK to the EGF-R has earlier
been reported to stimulate its phosphorylation with subse-
quent release of TGFK [45,46]. Currently, the mechanisms
which, in addition to the initial EGF-R phosphorylation, con-
tribute to the increased TGFK release and the second VEGF
peak after UVB irradiation are unclear. Other UVB-induced
cytokines or receptors with autocrine TGFK-inducing proper-
ties may play a role [47,48]. In this regard, keratinocyte
growth factor (KGF) receptor ligands like KGF and acidic
¢broblast growth factor (FGF) have been reported to induce
TGFK expression and activate the EGF-R signalling pathway
in cultured epidermal keratinocytes [47]. Furthermore, tumor
necrosis factor K regulates TGFK expression in hepatocytes
[48]. Alternatively, it might be possible that TGFK acts via a
receptor, which, distinct from the EGF-R, leads to the induc-
tion of the second VEGF peak.
Regardless of the exact mechanism, we here demonstrate a
biphasic response of VEGF induction upon UVB irradiation
at a physiological dose. Accordingly, the dose that stimulates
VEGF expression in human keratinocytes or HaCaT cells (10
mJ/cm2) is equivalent to the dose of UVB irradiation reached
at the skin surface after 1 min of sun exposure on a clear day
in July at noon at the latitude between 48 and 56 degrees
North [49,50]. In the here reported experiments, HaCaT cells
were directly irradiated. However, normal skin keratinocytes
are protected by the stratum corneum. Correction of the
wavelength e⁄ciencies (295^320 nm) determined in vitro
with the transmission spectrum of the overlying stratum cor-
neum and the upper epidermal cell layers [51] suggests that
about 6^18% of the incident UVB dose at the skin surface
reaches the keratinocytes beneath the stratum corneum.
Therefore, VEGF induction doses in vivo would require ap-
proximately 6^18 min of sun exposure. This time range ap-
plies for human sunbathing and is easily acquired during a
sunny summer day.
Even though we were recently able to show a causal role of
VEGF in UVB-induced angiogenesis in vivo (Blaudschun et
al., to be published elsewhere), it is most likely that apart
from VEGF, other factors are involved in the angiogenic
UVB response in vivo. In fact, basic FGF, a positive angio-
genic molecule, has been found to be induced upon UVB
irradiation of murine skin [52].
The biphasic UVB-induced VEGF expression is apparently
mediated by di¡erent though interrelated mechanisms. Ac-
cordingly, we found that the ¢rst peak of the biphasic
VEGF induction upon UVB irradiation is regulated by the
speci¢c phosphorylation and activation of the EGF-R and, in
contrast to the second VEGF peak, is independent of TGFK.
These data together with our previous ¢ndings (Blaudschun et
al., to be published elsewhere) indicate that the initial phos-
phorylation of the EGF-R occurring as early as 5 min pos-
tirradiation apparently, via the TGFK release at 6 h postirra-
diation with subsequent binding and activation of the EGF-R,
accounts at least in part for the observed second VEGF peak.
Collectively, we here provide a detailed molecular descrip-
tion for the regulation of VEGF that di¡erent from earlier
published results [53^55] may re£ect critical steps in UV-in-
duced angiogenesis in physiological and pathological condi-
tions.
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